Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling

J Am Coll Cardiol. 2001 Nov 1;38(5):1546-53. doi: 10.1016/s0735-1097(01)01591-1.

Abstract

Objectives: We sought to examine the role of the pro-inflammatory cytokine, interleukin-1-beta (IL-1beta), in the process of left ventricular (LV) remodeling in the early phase after myocardial infarction (MI).

Background: Studies have shown that pro-inflammatory cytokines are closely related to the progression of LV remodeling after MI.

Methods: Mice underwent coronary artery ligation, and the time course of LV remodeling was followed up to 20 weeks. The gene expression level of IL-1beta was examined. In a second set of experiments, the mice underwent coronary artery ligation followed by treatment with anti-IL-1beta antibody (100 microg, intravenously), versus control immunoglobulin G (100 microg, intravenously) immediately after the operation.

Results: Rapid hypertrophy of noninfarcted myocardium was observed by four weeks, and interstitial fibrosis progressed steadily up to 20 weeks. Anti-IL-1beta treatment increased the occurrence of ventricular rupture and suppressed collagen accumulation in the infarct-related area. At four and eight weeks after the operation, total heart weight and LV end-diastolic dimension were significantly greater in the anti-IL-1beta-treated mice than in the other groups. In the infarct-related area, collagen accumulation was suppressed, whereas in the noninfarcted area, pro-collagen gene expression levels, particularly type III, were decreased in the anti-IL-1beta-treated mice.

Conclusions: Anti-IL-1beta treatment suppressed pro-collagen gene expression and delayed wound healing mechanisms-properties that are likely to lead to progression of LV remodeling. In the acute phase of MI, IL-1beta appears to play a protective role.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use*
  • Cause of Death
  • Chronic Disease
  • Disease Models, Animal*
  • Disease Progression
  • Drug Evaluation, Preclinical
  • Echocardiography, Transesophageal
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / immunology
  • Hemodynamics / drug effects
  • Inflammation
  • Interleukin-1 / antagonists & inhibitors*
  • Interleukin-1 / genetics
  • Interleukin-1 / immunology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / immunology*
  • Myocardial Infarction / mortality
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Random Allocation
  • Rats
  • Survival Analysis
  • Time Factors
  • Ventricular Remodeling / drug effects*
  • Ventricular Remodeling / immunology*

Substances

  • Antibodies, Monoclonal
  • Interleukin-1